PPPriyanka A. Pophali

Priyanka A. Pophali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Priyanka A. Pophali has a total of 270 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL

    by Ajay Major, Diana Abbott, Jordan Snyder, Nausheen Ahmed, Alline Nogueira Serodio, Jose Caetano Villasboas, John Sharp, Timothy J Voorhees, Samin Houshyar, Danielle S Wallace, et al.

    Chimeric antigen receptor T-cell (CAR-T) and CD20xCD3 bispecific antibody (BsAb) therapies are both effective for relapsed/refractory (R/R) follicular lymphoma (FL), but comparative real-world survival outcomes and time toxicity have not been characterized. We performed a multicenter retrospective study of 228 patients with R/R FL treated with standard-of-care CAR-T (n = 141) or BsAb (n = 87) across 17 U.S. academic centers in the third-line or later setting. Progression-free survival (PFS) and overall survival (OS) were stratified by 2 or ≥3 prior lines of therapy (LOT2 or LOT3+), including propensity matching. Time toxicity was measured by physical health care contact days. Median PFS was not reached (NR) with CAR-T and 581 days with BsAb in the LOT2 cohort (p < .0001), and was NR with CAR-T and 584 days with BsAb in the LOT3+ cohort (p = .0064). CAR-T recipients were younger (p < .0001) and had better performance status (p = .007) but were more refractory to prior LOT (p = .017). PFS advantages of CAR-T were independent of these differences. OS did not differ between treatment groups. CAR-T had significantly greater time toxicity over the first year, with higher mean contact days than BsAb in both the LOT2 (58 vs 44) and LOT3+ (69 vs 49) cohorts. In this large multicenter cohort of patients with R/R FL, CAR-T was associated with superior PFS but greater time toxicity compared with BsAb therapy. These findings provide real-world outcomes data and time toxicity benchmarks to support treatment sequencing decision-making in R/R FL.

  • Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B-cell lymphoma in the era of CART and novel immunotherapies

    by Danny Trotier, Manlu Liu, Arun Augustine, Kiruba Vembu, Meaghan Trainor, Priyanka Pophali

    Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin’s lymphoma (NHL) and is the most common subtype, comprising 25% of all NHL cases [1]. The majority of patients diagnosed w...

  • Open Access

    Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma

    by Nausheen Ahmed, Alaa Ali, Soyoung Kim, Temitope Oloyede, Matthew Bye, Lohith Gowda, Rammurti T. Kamble, Abu-Sayeef Mirza, Kalyan V. Nadiminti, Priyanka A. Pophali, et al.

  • Open Access

    Neurotoxicity in Older Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Study

    by Aung M. Tun, Romil D. Patel, Frederique St-Pierre, Jenny Ouchveridze, Alex Niu, Thorunn Thordardottir, Jennifer Obasi, Allison Rosenthal, Priyanka A. Pophali, Timothy S. Fenske, et al.

  • Top Cited Papers
    Open Access

    Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma

    by Yucai Wang, Melissa C. Larson, Steven R. Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar, Ashlee Joseph, Taylor R. Brooks, Brian T. Hill, David A. Bond, et al.

    The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P< .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P< .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P< .001]; median OS, 136.1 vs 75.3 months [P< .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.


  • Open Access

    Cancer Survivorship Practices Among Cancer Care Providers and Cancer Centers in Brazil: Results From a National Survey

    by Cibele Barbosa Carroll, Juliana Ribeiro de Carvalho, Ana Luiza Cardona Miranda Machado, Kim Dittus, Priyanka Pophali, Noelle K. LoConte

    PURPOSE: Cancer survivorship evolved over the past few years in developed countries although in developing countries, guidelines and evidence-based recommendations on survivorship care are still lacking. We sought to gather information on cancer survivorship practices in Brazil to identify assets and areas for improvement. METHODS: Two surveys were developed regarding survivorship knowledge and the provision of services. Brazilian providers (physicians and nurses) and cancer center leaders received the surveys' invitation via WhatsApp groups of Brazilian oncology professionals. In addition, they were informed to share the study information with their networks (snowball sampling). The link to the surveys was advertised at Brazilian oncology conferences between August and December 2024. Descriptive statistics were used to summarize the results. RESULTS: Between August 13 and December 17, 2024, 194 unique providers and 28 cancer center leaders responded to the online survey. Among providers, 70% considered a cancer survivor a patient who completed cancer treatment and has no evidence of disease. The majority (60%) reported never consulting a survivorship guideline. The most common tool used to support survivors was a treatment summary (52.1%). Among cancer center leaders, 32.1% reported that their institutions have survivorship programs. The most common services offered to cancer survivors include medical follow-up, nutrition, and psychology services (100%), whereas reproductive medicine and sexual therapy were offered by 7.7% of cancer centers. Although 28.6% of the cancer center leaders reported that nurses specialized in oncology participate in follow-up care of cancer survivors who completed curative treatment, 14.9% of providers responded that these nurses are involved in survivorship follow-up. CONCLUSION: Cancer care providers and cancer centers from Brazil can benefit from culturally tailored survivorship guidelines to better address cancer survivors' needs.


  • Top Cited Papers

    Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

    by Taylor R. Brooks, Emily C. Zabor, Yohanna B. Bedelu, Xi Yang, Yasmin H. Karimi, Adrienne N. Nedved, Yucai Wang, Nikita Dave, Daniel J. Landsburg, Kelsey Baron, et al.

    Epcoritamab and glofitamab are CD20-directed bispecific antibodies (BsAbs) approved in the United States for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Limited data exist for patients treated outside of trials. Patients with R/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collected from 21 United States institutions. Among 245 patients, 156 received epcoritamab and 89 received glofitamab, 113 were refractory to front-line therapy, 40 had MYC and BCL2 and/or BCL6 rearrangements, 147 received prior chimeric antigen receptor T-cell therapy, and 174 patients would have been ineligible for registrational trials. The overall response rate (ORR) for epcoritamab and glofitamab was 51% (23% complete response, [CR]) and 53% (30% CR), respectively. Median progression-free survival (PFS) was 2.6 months (95% confidence interval [CI], 2.0-3.8 months), and median overall survival (OS) was 7.8 months (95% CI, 6.2-11.0 months). The 6-month PFS was 36% (95% CI, 30-44) and the 6-month OS was 60% (95% CI, 54-67). Both trial ineligibility and undetectable CD20 pre-BsAbs portended shorter PFS and OS. Of 17 individuals with paired biopsies, 15 (88.2%) lost CD20 expression after BsAbs with a median time to progression of 3.7 months. This analysis including patients with R/R DLBCL shows the ORR to CD3/CD20 BsAbs was comparable to pivotal trials, although PFS and OS were lower. Baseline undetectable levels of CD20 were associated with poor outcomes. These results demonstrate the activity of BsAbs in R/R DLBCL, and underscore the importance of target antigen expression.


  • Open Access

    CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma

    by Priyanka A. Pophali, Joshua A. Fein, Kwang Woo Ahn, Molly Allbee-Johnson, Nausheen Ahmed, Farrukh T. Awan, Shatha Farhan, Natalie S. Grover, Talal Hilal, Madiha Iqbal, et al.

    T-cell/histiocyte–rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19–directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. We investigated CART outcomes for R/R THRLBCL through the Center for International Blood and Marrow Transplant Research registry. A total of 58 adult patients with R/R THRLBCL who received commercial CD19-CART therapy between 2018 and 2022 were identified. Most patients (67%) had early relapse of disease (45% primary refractory) with a median of 3 (range, 1-7) prior therapies and were treated with axicabtagene ciloleucel (69%). At median follow-up of 23 months after CART therapy, 2-year overall and progression-free survival were 42% (95% confidence interval [CI], 27-57) and 29% (95% CI, 17-43), respectively. In univariable analysis, poor performance status before CART therapy was associated with higher mortality (hazard ratio, 2.35; 95%CI, 1.02-5.5). The 2-year cumulative incidences of relapse/progression and nonrelapse mortality were 69% and 2%, respectively. Grade ≥3 cytokine release syndrome and immune effector cell–associated neurologic syndrome occurred in 7% and 15% of patients, respectively. In this largest analysis of CD19-CART therapy for R/R THRLBCL, ∼30% of patients were alive and progression free 2 years after CART therapy. Despite a high incidence of progression (69% at 2 years), these results suggest a subset of patients with R/R THRLBCL may have durable responses with CARTs.


  • Anti‐CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study

    by Aung M. Tun, Romil D. Patel, Frederique St‐Pierre, Evguenia Ouchveridze, Alex Niu, Thorunn Thordardottir, Jennifer Obasi, Allison Rosenthal, Priyanka A. Pophali, Timothy S. Fenske, et al.

    Chimeric antigen receptor T‐cell (CAR‐T) therapy, despite being a potentially curative therapy in relapsed or refractory (RR) large B‐cell lymphoma (LBCL), remains underutilized in older patients due to limited clinical data. We therefore studied the safety and efficacy of CAR‐T therapy in older patients with RR LBCL in the real‐world setting. Patients aged ≥65 years with RR LBCL, treated with anti‐CD19 CAR‐T therapy at 7 US institutions were included in this multicenter, retrospective, observational study. In total, 226 patients were included. Median age at infusion was 71 years (range 65–89). Best objective and complete response rates were 86% and 62%, respectively. Median follow‐up after infusion was 18.3 months. The median progression‐free survival (PFS) was 6.9 months, with 6‐ and 12‐month PFS estimates of 54% and 44%, respectively. The nonrelapse mortality (NRM) rate was 10.9% at day 180, primarily due to infections, and not impacted by the age groups. Grade ≥3 cytokine release syndrome and neurotoxicity occurred in 7% and 26%, respectively. In univariate analysis, no significant difference in PFS was seen regardless of the age groups or CAR‐T type, whereas ECOG PS ≥2, elevated LDH, bulky disease, advanced stage, extranodal involvement, the need for bridging therapy, and prior bendamustine exposure were associated with shorter PFS. These findings support the use of CAR‐T in older patients, including those aged ≥80 years. The age at CAR‐T therapy did not influence safety, survival, and NRM outcomes. Older patients should not be excluded from receiving CAR‐T therapy solely based on their chronological age.